Comparative Pharmacology
Head-to-head clinical analysis: SCANLUX 370 versus UROVIST SODIUM 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SCANLUX 370 versus UROVIST SODIUM 300.
SCANLUX-370 vs UROVIST SODIUM 300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Radiopaque contrast agent that contains iodine, attenuates X-rays, enhancing vascular and tissue visualization during imaging.
Iodinated contrast agent that attenuates X-rays, improving visualization of vascular structures and organs during imaging.
The typical adult dose of SCANLUX-370 is 0.1 mg/kg administered intravenously as a single dose, up to a maximum of 7 mg.
Intravenous injection of 50-100 mL for contrast imaging, typically a single dose of 300 mg iodine/mL.
None Documented
None Documented
The terminal elimination half-life of SCANLUX-370 is approximately 1.5-2 hours in patients with normal renal function. This short half-life allows for rapid clearance and minimal accumulation with repeated dosing.
Terminal elimination half-life is approximately 2 hours in patients with normal renal function (GFR >90 mL/min). In renal impairment, half-life may be prolonged up to 10 hours or more, correlating with decreased GFR.
SCANLUX-370 is primarily eliminated via renal excretion, with approximately 85-90% of the dose recovered unchanged in urine within 24 hours. The remaining 10-15% is excreted unchanged in feces via biliary elimination.
Primarily renal (glomerular filtration), with >90% of the administered dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion is negligible (<5%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent